PNC-27 dosage chart

30 mg Vial

PNC-27 is dosed at 100 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 30 mg vial reconstituted with bacteriostatic water yields about 10 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
Typical daily range: 100–500 mcg once daily (gradual titration).
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
Dosing schedule: 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.

Dosing schedule

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg (0.10 mg)	1 unit (0.01 mL)
Weeks 3–4	200 mcg (0.20 mg)	2 units (0.02 mL)
Weeks 5–8	300 mcg (0.30 mg)	3 units (0.03 mL)
Weeks 9–12	400 mcg (0.40 mg)	4 units (0.04 mL)
Weeks 13–16	500 mcg (0.50 mg)	5 units (0.05 mL)

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl/roll until dissolved (do not shake).
4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Cycle & Timing

This protocol runs on a 5 days on / 2 days off cycle.

Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
Keep the dose time consistent on dosing days.
If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Regulatory Warning: PNC-27 has no FDA approval and no established human safety data. This information is strictly educational.

How This Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Potential Benefits & Side Effects

Observations from preclinical literature only—no human data available.

Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells.
Mechanism involves direct membrane lysis rather than apoptosis in affected cells.
No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established.
Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.

Lifestyle Factors

General supportive strategies (not specific to PNC-27).

Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
Prioritize adequate sleep and stress management for immune and recovery support.
Consult qualified healthcare professionals before any experimental peptide use.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

Important Note

This content is for educational purposes only and is not medical advice. PNC-27 is an unapproved experimental compound with no established human safety or efficacy data.

Supplies needed

Plan covers the full 16-week protocol at the lowest listed starting dose: 0.1 mg per dose, 5 days on / 2 days off (80 administrations in total), using 30 mg vials. After mixing with 3 mL, the concentration is 10 mg/mL and each dose requires 0.01 mL total.

PNC-27 vials (30 mg each)

Vials are rounded up only after calculating the whole protocol: ceil(8 ÷ 30) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (16 weeks): 1 vial (8 mg needed ÷ 30 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (16 weeks): 80 syringes

Bacteriostatic water (10 mL bottles)

Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).

Full protocol (16 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.

Full protocol (16 weeks): 160 swabs

Supply	Full protocol (16 weeks)
PNC-27 vials (30 mg each)Vials are rounded up only after calculating the whole protocol: ceil(8 ÷ 30) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.	1 vial (8 mg needed ÷ 30 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	80 syringes
Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.	160 swabs

PNC-27 dosage FAQs

How much bacteriostatic water do you use to reconstitute PNC-27?

Add 3.0 mL bacteriostatic water → 10 mg/mL concentration. for a 30 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

How often is PNC-27 administered in research protocols?

Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).

What does the PNC-27 dosing schedule look like?

Weeks 1–2 — 100 mcg (0.10 mg) — 1 unit (0.01 mL); Weeks 3–4 — 200 mcg (0.20 mg) — 2 units (0.02 mL); Weeks 5–8 — 300 mcg (0.30 mg) — 3 units (0.03 mL); Weeks 9–12 — 400 mcg (0.40 mg) — 4 units (0.04 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for PNC-27?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).

How should reconstituted PNC-27 be stored?

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..

How many insulin syringe units equal a PNC-27 dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is PNC-27 approved for human use?

No. PNC-27 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.